Open AccessAre Drug Eluting Stents Worth Triple Therapy?
Author(s) -
Heidenreich Paul
Publication year - 2017
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.117.006983
Subject(s) - medicine , restenosis , percutaneous coronary intervention , stent , drug eluting stent , surgery , cardiology , myocardial infarction
Approximately 8% patients undergoing percutaneous coronary intervention are on anticoagulation, which creates difficult choices regarding stent type and antiplatelet use.[1][1] Drug eluting stents (DES) are usually preferred over bare metal stents (BMS) because of less restenosis and fewer repeat